Antiretroviral News and Research RSS Feed - Antiretroviral News and Research

Mylan receives shareholders' approval for proposed Perrigo acquisition

Mylan receives shareholders' approval for proposed Perrigo acquisition

Mylan N.V. today announced that its shareholders have approved Mylan's proposed acquisition of Perrigo Company plc and the related issuance of Mylan ordinary shares to Perrigo's shareholders at an extraordinary general meeting of shareholders held today. [More]
New studies evaluate viral suppression rate of HIV-infected pregnant women at delivery

New studies evaluate viral suppression rate of HIV-infected pregnant women at delivery

Pregnancy could be a turning point for HIV-infected women, when they have the opportunity to manage their infection, prevent transmission to their new baby and enter a long-term pattern of maintenance of HIV care after giving birth--but most HIV-infected women aren't getting that chance. [More]
Mylan releases generic version of Zosyn Injection in the U.S.

Mylan releases generic version of Zosyn Injection in the U.S.

Mylan N.V. today announced the U.S. launch of Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials, which is the generic version of Pfizer's Zosyn Injection. [More]
Alere's HIV diagnostics products recognised with Frost & Sullivan's 2015 Product Line Strategy Leadership award

Alere's HIV diagnostics products recognised with Frost & Sullivan's 2015 Product Line Strategy Leadership award

Based on its recent analysis of the HIV diagnostics market, Frost & Sullivan recognises Alere with the 2015 African Frost & Sullivan Award for Product Line Strategy Leadership. Alere has marched steadily to the top of the HIV diagnostic space with its array of testing products that deliver accurate results and leverage cost-effective technologies. It has one of the largest ranges of HIV diagnostic products in the African region. [More]
Mylan sued in connection with ANDA filing for generic version of Zytiga

Mylan sued in connection with ANDA filing for generic version of Zytiga

Mylan N.V. today confirmed that the company has been sued by BTG International Ltd., Janssen Biotech, Inc., Janssen Oncology, Inc., and Janssen Research & Development, LLC in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for Abiraterone Acetate Tablets, 250 mg. [More]
Ontario nearing ambitious UN targets for ending AIDS epidemics

Ontario nearing ambitious UN targets for ending AIDS epidemics

A new study suggests Ontario is nearing ambitious United Nations targets for ending the AIDS epidemics: By 2020, 90 per cent of all people living with HIV should know their HIV status, 90 per cent of all people diagnosed with HIV are receiving sustained antiretroviral drug therapy and 90 per cent of people on ART have a very low or undetectable levels of the virus. [More]
PHIV children may lack immunity against measles, mumps, and rubella despite vaccination

PHIV children may lack immunity against measles, mumps, and rubella despite vaccination

Between one-third and one-half of individuals in the United States who were infected with HIV around the time of birth may not have sufficient immunity to ward off measles, mumps, and rubella--even though they may have been vaccinated against these diseases. [More]
Mylan announces launch of Lidocaine Patch 5% in the U.S.

Mylan announces launch of Lidocaine Patch 5% in the U.S.

Mylan N.V. today announced the U.S. launch of its Lidocaine Patch 5%, which is the generic version of Endo Pharmaceutical's Lidoderm. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for relief of pain associated with post-herpetic neuralgia. [More]

Mylan announces launch of Esomeprazole Magnesium Delayed-release Capsules USP in U.S.

Mylan N.V. today announced the U.S. launch of Esomeprazole Magnesium Delayed-release Capsules USP, 20 mg and 40 mg, which is the generic version of AstraZeneca's Nexium. [More]
Northwestern gets $17.5 million NIH grant to invent, develop implantable drug delivery system for HIV prevention

Northwestern gets $17.5 million NIH grant to invent, develop implantable drug delivery system for HIV prevention

Northwestern Medicine scientists have received a five-year, $17.5 million grant from the National Institutes of Health for an interdisciplinary project that aims to invent, develop and test an implantable drug delivery system to protect high-risk individuals from HIV infection for up to a year at a time. [More]

Pitt investigators to lead $5 million initiative to monitor resistance to HIV prevention drugs in sub-Saharan Africa

Infectious diseases researchers from the University of Pittsburgh School of Medicine are leading a five-year, $5 million initiative to monitor drug resistance during the rollout of HIV prevention drugs in sub-Saharan Africa. [More]

Mylan receives regulatory clearance from European Commission for proposed acquisition of Perrigo

Mylan N.V. today announced that it received regulatory clearance from the European Commission under the European Union Merger Regulation (EUMR) for its proposed acquisition of Perrigo Company plc. [More]
Screening for HIV in pregnancy eliminates vertical transmission

Screening for HIV in pregnancy eliminates vertical transmission

Canada has almost eliminated mother-to-child HIV transmission, known as vertical transmission, in recent years by ensuring that all women have the opportunity to be screened for HIV in pregnancy and that women with the disease receive treatment before giving birth. [More]

Study: Cash to stay in school did not reduce HIV risk among young women in South Africa

A Phase III, individually randomized trial has found conditional cash transfers for school attendance did not reduce the risk of HIV among high-school aged women in South Africa, investigators from the HIV Prevention Trials Network (HPTN) reported today at the 8th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, Canada. [More]
InnaVirVax presents positive results of IVVAC-3S/P1 study at International AIDS Society Conference

InnaVirVax presents positive results of IVVAC-3S/P1 study at International AIDS Society Conference

InnaVirVax, a biopharmaceutical company specialized in research and development of therapeutic and diagnostic solutions for major infectious and chronic diseases, today announced the overall results of its Phase I/IIa clinical study of its VAC-3S immunotherapy, which is currently in development. [More]
Early antiretroviral treatment prevents AIDS- and non-AIDS-related diseases in HIV-infected people

Early antiretroviral treatment prevents AIDS- and non-AIDS-related diseases in HIV-infected people

Starting antiretroviral therapy early not only prevents serious AIDS-related diseases, but also prevents the onset of cancer, cardiovascular disease, and other non-AIDS-related diseases in HIV-infected people, according to a new analysis of data from the Strategic Timing of AntiRetroviral Treatment (START) study, the first large-scale randomized clinical trial to establish that earlier antiretroviral treatment benefits all HIV-infected individuals. [More]
Beckman Coulter announces expansion of Cellular Accessible Retroviral Evaluation Systems Initiative at International AIDS Society 2015

Beckman Coulter announces expansion of Cellular Accessible Retroviral Evaluation Systems Initiative at International AIDS Society 2015

Beckman Coulter Life Sciences today announces an expansion of its CARES (Cellular Accessible Retroviral Evaluation Systems) Initiative at the 2015 International AIDS Society (IAS) Conference, being held at the Vancouver Convention Centre from July 19-22, 2015 in Vancouver, Canada. CARES focuses on providing innovative solutions for the monitoring of HIV and AIDS treatment in Africa. [More]
Phase II open-label study demonstrates that high-risk populations adhere well to daily regimen of PrEP

Phase II open-label study demonstrates that high-risk populations adhere well to daily regimen of PrEP

Results from HPTN 067, a Phase II, randomized, open-label study, demonstrate most study participants had higher coverage of sex events and better adherence when they were assigned to the daily dosing arm, investigators from the HIV Prevention Trials Network (HPTN) reported today at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, Canada. [More]
Study findings provide basis for potential development of new methods to control HIV infection

Study findings provide basis for potential development of new methods to control HIV infection

Lower levels of cholesterol in certain immune cells--a result of enhanced cholesterol metabolism within those cells--may help explain why some HIV-infected people are able to naturally control disease progression, according to research that will be presented in a poster at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) in Vancouver, Canada, and the pre-conference 2015 Towards an HIV Cure Symposium. [More]
Canadian researchers discover how HIV evades the body's antiviral responses

Canadian researchers discover how HIV evades the body's antiviral responses

A Canadian research team at the IRCM in Montreal, led by molecular virologist Eric A. Cohen, PhD, made a significant discovery on how HIV escapes the body's antiviral responses. The team uncovered how an HIV viral protein known as Vpu tricks the immune system by using its own regulatory process to evade the host's first line of defence. [More]
Advertisement